# Ottobock account plan

> Ottobock is a German maker of prosthetics, orthotics and exoskeletons with a patient care network; 2025 revenue was € 1,679.8 million.

## At a glance

Ottobock SE & Co. KGaA, based in Duderstadt, Germany, develops and makes prosthetics, neuro-orthotics, digital orthotics and prosthetics (O&P) solutions and occupational exoskeletons, and runs the Ottobock.care network of over 420 clinics and satellites in 33 countries. Its customers are O&P professionals, distributors, public institutions and amputee and neurological patients; with partners it reached patients in more than 132 countries in 2025. FY2025 revenue was € 1,679.8 million (+4.7%), core revenue € 1,599.7 million and underlying core EBITDA € 415.3 million (26.0% margin), with an average headcount of 9,275 FTE. It has been listed on the Frankfurt Stock Exchange since 9 October 2025; the Näder Family Office holds 82.44%.

## Business units

- **EMEA** (71.4% of 2025 group revenue (€ 1,199.7 million)): Europe, Middle East and Africa host headquarters, the central distribution hub and most production sites, including the low-cost Bulgarian platform. Revenue grew 10.9% to € 961.4 million in January-September 2026, with B2B organic growth of 14.4% and softer Western Europe due to reimbursement processes; Russia contributed more than 11% of group revenue.
- **Americas** (21.9% of 2025 group revenue (€ 368.2 million)): North and South America, where 2025 B2B growth came from Genium X4, Kenevo reimbursement for K2 amputees in the U.S. and the C-Brace. Revenue fell 3.3% to € 257.6 million in January-September 2026, with U.S. B2B flat on customer destocking, the end of a Canadian programme and delayed tenders in Brazil.
- **APAC** (6.7% of 2025 group revenue (€ 111.9 million)): Asia Pacific, with local production in Tongzhou, China and demand for microprocessor knees. Revenue grew 5.8% to € 88.9 million in January-September 2026, accelerating in Q3 on tender catch-up in Australia and Thailand.
- **Products & components (B2B)** (53.4% of 2025 revenue (€ 896.2 million)): Prosthetics (Genium X4 and Kenevo knees, Taleo feet, the michelangelo hand), neuro-orthotics (C-Brace, Exopulse Suit), digital O&P and SuitX exoskeletons; Ottobock holds around 35% to 40% of the B2B market. Revenue grew 9.1% to € 709.3 million in January-September 2026.
- **Patient care (B2C)** (41.9% of 2025 revenue (€ 703.4 million)): The Ottobock.care clinic network fitting amputees and people with neurological mobility constraints; Ottobock is the second-largest provider in this fragmented market with approximately 5%. Revenue grew 6.9% to € 542.6 million in January-September 2026, with organic growth of 3.3%.

## Strategic priorities

- **Innovation and reimbursement**: Ottobock aims to advance the standard of care in prosthetics and neuro-orthotics through new products and reimbursement wins; it launched 29 new or upgraded products in 2025 and the michelangelo hand, iconiq liner and C-Brace Interim at OTWorld in 2026.
- **Patient care network expansion**: Forward integration to expand, integrate and digitalise the B2C network, including the Ottobock.care brand roll-out, IT harmonisation in U.S. clinics and acquisitions such as Blatchford Norway and Rehattiva.
- **Operational efficiency**: The GVEM programme, the Bulgarian shared service center and SAP S/4HANA support a margin target of 29 to 30% adjusted EBITDA in 2029.
- **Digital O&P and AI**: Ottobock is building an end-to-end digital patient care chain, with AI-supported Smart Documentation launched in 2025 and AI tools now preparing reimbursement approval requests.
- **Portfolio focus**: The Human Mobility wheelchair business is being sold to DH Care with closing targeted by year-end, so that from 2027 Ottobock reports only its core business.

## Latest results

In January-September 2026 revenue rose 7.4% to € 1,307.9 million and core revenue 8.1% to € 1,251.8 million, with organic core growth of 6.6%. Underlying core EBITDA rose 16.4% to € 327.1 million, a 26.1% margin, and net income reached € 115.1 million. Q3 was partly below management's expectation because of a tougher reimbursement environment in Western Europe and the U.S. The 2026 guidance of 6%-8% organic core growth and an underlying core EBITDA margin above 27.0% was confirmed, though the CEO expects full-year growth between 6% and 7%.

## Investments and deals

- **Blatchford Norway acquisition**: On 13 May 2026 Ottobock bought 100% of Blatchford Norway AS, a Norwegian patient care brand, for € 115.3 million in cash.
- **Fesia and Rehattiva acquisitions**: In July 2026 Ottobock agreed to buy Fesia Technology S.L. (Spain, functional electrical stimulation) for a preliminary € 15.0 million plus earn-out, and acquired Rehattiva Srl, an Italian patient care business.
- **Neural interface ventures**: A € 4.4 million stake in Blue Arbor Technologies in February 2026, following 2025 stakes in Bionic Skins, Musclemetrix and Phantom Neuro and a € 10.0 million follow-on in ONWARD Medical.
- **Capex and R&D**: CapEx was € 105.2 million in 2025 and R&D expenses € 72.7 million plus € 54.1 million capitalised; net CapEx and capitalised R&D stay at EUR 105-150 million for 2026.
- **IPO**: The October 2025 IPO at € 66.00 per share placed 12,236,173 shares (€ 807.6 million).

## Challenges and risks

- **Tighter reimbursement**: Germany plans a reduction of approximately 3% in reimbursement rates from 2027, France cut the price of the C-Leg and Belgium cut its budget; converting a patient to revenue now takes about three months instead of one.
- **U.S. approval delays and destocking**: The Genium X4 is reimbursed under a miscellaneous code, so each fitting needs separate approval, and U.S. customers adjusted inventories.
- **Russia exposure**: Russia was more than 11% of group revenue in January-September 2026, bringing sanctions risk and short-seller allegations that the CFO rejects.
- **Supply and cyber risks**: The largest risks in the 2025 matrix are supplier dependencies and supply shortages, IT failures from cyber-attacks and data protection penalties.
- **Slower patient care growth**: B2C organic growth of 3.3% in nine months was below the company's ambition, partly due to longer approvals in Germany, France and Belgium.

## What leadership says

> "Our success is based on the interplay of technological excellence, integrated value creation, and immediate proximity to application" — Oliver Jakobi, CEO and Chief Sales Officer, Interview in the Annual Report 2025, March 2026

> "A 3% haircut, what we are now expecting in Germany, a year ago, was not anticipated." — Oliver Jakobi, CEO and Chief Sales Officer, Q3 2026 earnings call, 12 November 2026

> "Strategically and operationally, we are fully on track." — Oliver Jakobi, CEO, H1 2026 earnings call, 13 August 2026

> "We're not expecting a margin decline" — Dr. Arne Kreitz, CFO, Q3 2026 earnings call, 12 November 2026, on 2027


## Where a supplier can help

- **Reimbursement automation**: Tied to tighter reimbursement and U.S. approval delays: documentation, payer-communication and revenue-cycle tools can shorten the approval period Ottobock is already tackling with AI.
- **Clinic IT and integration**: Tied to patient care network expansion and recent acquisitions: clinic management software, IT harmonisation and integration services fit the growing Ottobock.care network.
- **Finance and ERP transformation**: Tied to operational efficiency: the SAP S/4HANA implementation and the Bulgarian shared service center create needs for ERP, process and shared-services suppliers.
- **Supply chain resilience**: Tied to supplier dependencies and supply shortages: second sourcing, components and supply chain visibility tools address the top-ranked risk.
- **Cybersecurity and data protection**: Tied to cyber and GDPR/NIS-2 risks: security and compliance providers fit a group running clinics and connected products.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report 2025](https://investors.ottobock.com/media/document/38c192af-6c30-412b-937d-f6d40f71b47e/assets/DE000BCK2223-JA-2025-EQ-E-00.pdf)

Annual report · 2026-03-19

- Ottobock is a Duderstadt-based MedTech group and, by its own account, the global market leader in human bionics: prosthetics, neuro-orthotics, digital O&P and occupational exoskeletons (B2B), plus the Ottobock.care patient care network (B2C) with over 420 clinics and satellites in 33 countries.
- FY2025 revenue was € 1,679.8 million (+4.7%); core revenue € 1,599.7 million (+11.7%), with organic core growth of 10.6%, in the upper half of the 9-12% IPO guidance.
- Underlying core EBITDA rose 29.5% to € 415.3 million, a 26.0% margin (2024: 22.4%); net income € 88.3 million; free cash flow € 228.0 million; leverage down to 2.3x (2024: 3.5x).
- Products & components (B2B) € 896.2 million (+14.5%, organic 15.2%) is the growth and margin engine; patient care (B2C) € 703.4 million (+8.3%); non-core € 80.2 million after the Cascade sale and the Active Life closure.
- EMEA is 71.4% of revenue, Americas 21.9%, APAC 6.7%; growth came from Genium X4, the Taleo family, Kenevo reimbursement for K2 amputees in the U.S., C-Brace reimbursement in France and spike events.
- IPO on 9 October 2025 at € 66.00 (€ 807.6 million placed, about € 100 million primary); the Näder Family Office keeps 82.44%; included in SDAX and TecDAX; dividend proposal € 0.97 per share.
- Strategy: technology leadership and reimbursement expansion in B2B, forward integration and digitalisation of the B2C network, and the GVEM efficiency programme (shared service center and production shift to Bulgaria).
- 2026 guidance: organic core revenue growth of 5% to 8% and an underlying core EBITDA margin above 26.5%; the human mobility (wheelchair) business is being sold.
- Main risks named: supplier dependencies, IT failures and cyber-attacks, data protection penalties; also wars/conflicts and Russia sanctions, U.S. tariffs, reimbursement changes.

### [Interim Financial Report H1 2026 (30 June 2026)](https://investors.ottobock.com/media/document/00d32b41-40bc-416b-bc64-5de40f823e5b/assets/DE000BCK2223-Q2-2026-EQ-E-00.pdf)

Interim report · 2026-08-13

- H1 2026 revenue rose 6.7% to € 854.1 million; core revenue € 818.5 million (+7.7%), with organic core growth of 6.7% (H1 2025: 10.9%) and 8.0% in Q2.
- Underlying core EBITDA rose 18.1% to € 207.0 million; the margin improved to 25.3% (23.1%), and to 27.9% in Q2.
- Net income more than doubled to € 67.3 million (+140.7%); underlying net income € 85.1 million; EPS € 1.06.
- EMEA grew 11.3% (organic core 9.0%, B2B organic 14.5%); the Americas fell 6.0% with organic core growth of -0.3%; APAC -0.8% reported, organic core 3.6%.
- B2B € 461.6 million (organic 8.7%) driven by Genium X4, Kenevo and C-Brace; B2C € 356.9 million (organic 4.2%).
- Guidance specified: organic core revenue growth of 6.0-8.0% and an underlying core EBITDA margin above 27.0% (from 5-8% and above 26.5%).
- Deals: Blatchford Norway acquired in May 2026 (€ 115.3 million consideration), a € 4.4 million stake in Blue Arbor Technologies, the Human Mobility wheelchair sale signed on 19 June 2026, and Fesia Technology (Spain) signed on 7 July 2026.
- Free cash flow fell to € 71.8 million on higher tax payments; leverage 2.5x; equity ratio 17.8%.

### [Quarterly Statement January - September 2026](https://investors.ottobock.com/media/document/4e4cb1ce-2691-4c63-aecc-af38bd6c7977/assets/DE000BCK2223-Q3-2026-EQ-E-00.pdf)

Interim report · 2026-11-12

- 9M 2026 revenue rose 7.4% to € 1,307.9 million; core revenue € 1,251.8 million (+8.1%), organic core growth 6.6% (9M 2025: 11.5%); Q3 organic core growth 6.4%.
- Underlying core EBITDA rose 16.4% to € 327.1 million; margin 26.1% (24.3%), and 27.7% in Q3.
- Net income € 115.1 million (+111.9%); underlying net income € 138.0 million; EPS € 1.79.
- EMEA organic core growth 8.7%, helped by double-digit B2B growth with Russia and Ukraine contributing; Western Europe softer as reimbursement processes lengthened. Russia contributed more than 11% of group revenue.
- Americas organic core growth -0.8% (B2B down against a strong comparison); APAC 8.6% after Q3 momentum.
- B2B € 709.3 million (organic 9.1%, michelangelo hand among drivers); B2C € 542.6 million (organic 3.3%).
- Free cash flow € 151.1 million (€ 172.8 million) on € 33.9 million higher tax payments; leverage 2.3x.
- Guidance confirmed: organic core revenue growth 6-8%, underlying core EBITDA margin above 27.0%; Rehattiva (Italy) acquired in July.

### [Q3 2026 earnings call transcript](https://stockanalysis.com/quote/etr/OBCK/transcripts/673407-q3-2026/)

Executive talk · Oliver Jakobi, CEO and Chief Sales Officer · 2026-11-12

- CEO Oliver Jakobi said Q3 "was partly below our expectation due to the changed reimbursement environment"; 9M organic core growth 6.6%, Q3 6.4%.
- Guidance of 6%-8% growth and a margin above 27% confirmed, but Jakobi now expects full-year 2026 growth "between 6% and 7%".
- Reimbursement pressure in Western Europe: an approximately 3% cut in German rates from 2027, price cuts in France (C-Leg) and Belgium (budget), and longer approval times in Germany, France, Belgium and the U.S.
- Management sees a probable impact of about 1 percentage point on growth; 2027 and midterm guidance will come in March 2027.
- Russia contributed 3.5 points of EMEA's 8.7% growth; "spike events" will no longer be reported separately because the Ukraine/Russia patient base is now normal business.
- B2B grew 9.1% (Q3 9.9%) and is the growth engine; Patient Care 3.3% (Q3 1.7%) is below ambition; the Americas fell 0.8% on U.S. destocking, the end of Canada's War Amps program and delayed Brazilian tenders.
- CFO Arne Kreitz: margin drivers (mix, scale, efficiency) stay intact, "We're not expecting a margin decline"; leverage target below 2x at year-end; a 25% effective tax rate remains the guide.
- Countermeasure: AI tools and an ambient listening tool to prepare reimbursement approval requests and shorten approval times next year.

### [H1 2026 earnings call transcript](https://stockanalysis.com/quote/etr/OBCK/transcripts/557852-q2-2026/)

Executive talk · Oliver Jakobi, CEO · 2026-08-13

- CEO Oliver Jakobi: "Strategically and operationally, we are fully on track"; H1 organic core growth 6.7%, Q2 8%, with Q1 timing effects normalised.
- Guidance narrowed: growth range lifted at the low end from 5% to 6% (top stays 8%); margin guidance raised to above 27% from above 26.5%.
- Underlying EBITDA margin 25.3% in H1 and 27.9% in Q2; CFO Arne Kreitz targets roughly 1 point of margin gain per year in the midterm and leverage below 2x by year-end.
- B2B grew 8.7% in H1 and 11.7% in Q2, broad-based across high-end mechatronics, feet, liners, new mechanical knees and the Michelangelo Hand.
- U.S. B2B grew 1% in H1, with what the CFO called a catch-up to 4% in Q2; Canada (War Amps program on hold) and Brazil (no tenders before elections) weighed on the Americas.
- M&A: Blatchford's patient care business in Norway (market leader, margin similar to B2B) and Fesia (functional electrical stimulation); expected to beat the 8.5-9% WACC.
- Human Mobility wheelchair business sold to DHCare, closing expected at year-end; from next year only the core business will be reported.
- Spike events add 1-2 points of EMEA's 9% growth; Ukraine has about 150,000 new amputees since the war began versus 8,000-10,000 fittings a year before.

### [Ottobock-CFO zieht positives Fazit nach einem Jahr Börsennotierung (Börsen-Zeitung interview)](https://www.boersen-zeitung.de/unternehmen-branchen/ottobock-finanzchef-zieht-positive-bilanz-aus-erstem-boersenjahr)

Executive talk · Arne Kreitz, Chief Financial Officer · 2026-09-11

- CFO Arne Kreitz, a year after the October 2025 IPO, says (translated) "We have delivered what we promised", with the share about 15% below the € 66 issue price, which he puts down to sector-wide derating and capital flowing to tech and energy.
- The IPO brought financial and strategic flexibility (e.g. human-machine interfaces), capital market discipline and visibility, including with job applicants; only about € 100 million of the € 808 million proceeds went to Ottobock.
- 2026 deals: Blatchford's Norwegian patient care business for € 110 million, Fesia Technology (functional electrical stimulation) and a $5 million stake in Blue Arbor Technologies.
- Midterm targets: organic growth of 7-9% a year to 2029 and an adjusted EBITDA margin of 29-30% in 2029, from scale, mix and efficiency (over 600 staff in Bulgaria).
- Ottobock is about twice the size of the next player in products and components; the U.S. remains the key Americas market; Canada and Brazil were H1 one-offs.
- Leverage near 2x at year-end; an € 850 million syndicated loan to 2029 with an accordion; no bond or rating needed; dividend 30-40% of adjusted net income, but growth has priority.
- The Human Mobility sale to DH Care removes € 64 million of 2025 revenue with very low EBITDA; Orthopedic Services (about € 10 million revenue, U.S.) remains non-core.
- Russia was 8.8% of revenue at the IPO and slightly above 10% in H1 2026; Kreitz rejects Grizzly Research's claims and says Ottobock filed a market manipulation complaint with BaFin.

## Questions about Ottobock

### What does Ottobock do?

Ottobock develops and makes prosthetics, neuro-orthotics, digital O&P solutions and exoskeletons, and fits patients through its Ottobock.care network of over 420 clinics and satellites in 33 countries.

### What is Ottobock's revenue?

FY2025 revenue was € 1,679.8 million (+4.7%). In January-September 2026 revenue was € 1,307.9 million (+7.4%).

### How many employees does Ottobock have?

Average headcount was 9,275 FTE in 2025 and average FTE was 9,455 in January-September 2026.

### Who leads Ottobock?

Oliver Jakobi is CEO and Chief Sales Officer, Dr. Arne Kreitz is CFO, and Prof. Hans Georg Näder chairs the Management Board of the general partner.

### What is Ottobock's strategy?

Three pillars: innovation and technology leadership scaled through B2B, forward integration of the patient care network, and operational excellence, with a target of 29 to 30% adjusted EBITDA margin in 2029.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
